LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Novo Nordisk A-S

Geschlossen

BrancheGesundheitswesen

67.74 0.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

67.19

Max

68.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

804M

29B

Verkäufe

-7.6B

78B

KGV

Branchendurchschnitt

19.207

50.291

EPS

6.53

Dividendenrendite

2.32

Gewinnspanne

37.182

Angestellte

77,406

EBITDA

5.9B

46B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+40.74% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.32%

2.40%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

43B

309B

Vorheriger Eröffnungskurs

67.13

Vorheriger Schlusskurs

67.74

Nachrichtenstimmung

By Acuity

80%

20%

359 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Novo Nordisk A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Mai 2025, 11:36 UTC

Top News

Novo Nordisk CEO to Step Down Amid Market Challenges

12. Mai 2025, 09:36 UTC

Wichtige Markttreiber

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7. Mai 2025, 11:29 UTC

Top News
Ergebnisse
Wichtige Markttreiber

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

24. Juni 2025, 10:26 UTC

Market Talk

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23. Juni 2025, 13:09 UTC

Market Talk

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20. Juni 2025, 13:31 UTC

Akquisitionen, Fusionen, Übernahmen

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13. Juni 2025, 11:39 UTC

Market Talk

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13. Juni 2025, 10:04 UTC

Market Talk

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11. Juni 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10. Juni 2025, 13:38 UTC

Heiße Aktien

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9. Juni 2025, 10:09 UTC

Market Talk

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3. Juni 2025, 15:03 UTC

Akquisitionen, Fusionen, Übernahmen

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29. Mai 2025, 01:00 UTC

Top News

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20. Mai 2025, 14:08 UTC

Ergebnisse

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20. Mai 2025, 07:43 UTC

Market Talk

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16. Mai 2025, 18:35 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16. Mai 2025, 17:34 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16. Mai 2025, 13:42 UTC

Heiße Aktien

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16. Mai 2025, 13:27 UTC

Market Talk

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16. Mai 2025, 13:15 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16. Mai 2025, 12:17 UTC

Ergebnisse

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. Mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7. Mai 2025, 15:13 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. Mai 2025, 13:45 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7. Mai 2025, 11:25 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7. Mai 2025, 11:18 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S Prognose

Kursziel

By TipRanks

40.74% Vorteil

12-Monats-Prognose

Durchschnitt 94.79 USD  40.74%

Hoch 142.564 USD

Tief 61 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

4

Buy

3

Halten

1

Sell

Technischer Score

By Trading Central

62.63 / 69.23Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

359 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.